ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens.

ADVENTRX currently is focused on commercializing two late-stage product candidates in the U.S., ANX-530 (vinorelbine emulsion) and ANX-514 (docetaxel emulsion), both of which are reformulations of currently approved products.